阳光诺和子公司拟转让美速科用70%股权

Core Viewpoint - Sunshine Nuohuo (688621) announced the transfer of 70% equity in Shanghai Meisuke Data Co., Ltd. to Beijing Zhongjian Peilian Medical Research Institute for 2 million yuan, aiming to improve asset operation efficiency and reduce management costs due to Meisuke's long-term losses [1] Group 1 - Sunshine Nuohuo's wholly-owned subsidiary, Beijing Nuohuo Demai Pharmaceutical Technology Co., Ltd. (referred to as "Nuohuo Demai"), signed an equity transfer agreement with Zhongjian Peilian [1] - The decision to transfer the equity is based on the long-term loss status of Meisuke, with the goal of enhancing the company's sustainable operation capabilities [1] - The transaction also involves the transfer of part of the fundraising project related to the "Clinical Trial Service Platform Construction Project," of which Meisuke is one of the implementing entities [1]